

# Drug Coverage Decision for B.C. PharmaCare

## About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

## Details of Drug Reviewed

<b>Drug</b>	<b>somatropin</b>
Brand Name	Genotropin®
Dosage Form(s)	5.3 mg, 12 mg GoQuick™ pen 0.6 mg, 0.8 mg, 1.0 mg, 1.2 mg, 1.4 mg, 1.6 mg, 1.8 mg, 2.0 mg MiniQuick™ syringe
Manufacturer	Pfizer Canada Incorporated
<b>Submission Review</b>	<b>New Submission</b>
Use Reviewed	Treatment of adult growth hormone deficiency
Common Drug Review (CDR)	Yes. CDR recommended to list in a manner similar to other somatropin products for the treatment of adults with growth hormone deficiency. Visit CDR website for more details: <a href="http://www.cadth.ca/media/cdr/complete/SR0332_complete_Genotropin-GHD-Adults_Dec-23-13.pdf">http://www.cadth.ca/media/cdr/complete/SR0332_complete_Genotropin-GHD-Adults_Dec-23-13.pdf</a>
Drug Benefit Council (DBC)	DBC met on February 17, 2014. DBC considered various inputs including the final review completed by the Common Drug Review (CDR) on December 20, 2013, which included clinical and pharmacoeconomic evidence review material, Clinical Practice Reviews from two Specialists, Manufacturer comments; responses to Patient Input Questionnaires from 5 patient caregivers, and a Budget Impact Analysis.
<b>Drug Coverage Decision</b>	<b>Non-benefit</b>
Date	August 5, 2014
Reason(s)	<p><b>Drug coverage decision is consistent with the DBC recommendation.</b></p> <ul style="list-style-type: none"> <li>• The results from studies of this drug in the treatment of adults with growth hormone deficiency were inconsistent.</li> <li>• Other somatropin products were previously reviewed by the Ministry for the treatment of this indication with a decision not to provide coverage due to insufficient evidence of clinical benefit.</li> <li>• There is limited information regarding the cost-effectiveness of somatropin therapy in adults with growth hormone deficiency.</li> </ul>
Other Information	None

### The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council](#) gives advice to the Ministry. The Council looks at:

- advice from a national group called the Common Drug Review
- whether the drug is safe and effective
- whether it is a good value for the people of B.C. and the drugs cost
- the ethics of covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a decision based on many factors, including:

- advice from the Council
- drugs used to treat similar medical conditions that B.C. PharmaCare already covers
- the overall cost of covering the drug

For more information about the B.C. Drug Review Process, please visit  
<http://www.health.gov.bc.ca/pharmacare/outgoing/drugrevproc2.pdf>.

To find out more about the Pharmaceutical Services Division and the PharmaCare program, visit  
[www.health.gov.bc.ca/pharmacare](http://www.health.gov.bc.ca/pharmacare).

**This document is intended for information only.**

It does not take the place of advice from a physician or other qualified health care provider.